tolvaptan has been researched along with Fibrosis in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, X; He, Y; Wu, Q; Yan, F; Zhu, H | 1 |
| Nitta, K; Ogawa, T | 1 |
| Li, G; Liu, R; Ma, Z; Wang, W; Yuan, M; Zhang, K; Zhang, Y | 1 |
| Aonuma, K; Chiba, H; Ishizu, T; Namekawa, M; Sai, S; Seo, Y | 1 |
| Joseph, J; Joseph, L; Zhang, L | 1 |
| Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Miura, K; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamazaki, T; Yoshiyama, M | 1 |
| Akahoshi, Y; Fujiki, H; Ikeda, T; Iwanaga, Y; Miyazaki, S; Morooka, H; Watanabe, H | 1 |
| Greenberg, A; Verbalis, JG | 1 |
2 review(s) available for tolvaptan and Fibrosis
| Article | Year |
|---|---|
Clinical Impact of Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Calcimimetic Agents; Calcium Channel Blockers; Diet, Sodium-Restricted; Diuretics; Echocardiography; Echocardiography, Doppler; Fibrosis; Heart Failure, Diastolic; Histamine Antagonists; Humans; Hypertrophy, Left Ventricular; Myocardium; Renal Dialysis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Tolvaptan; Ventricular Dysfunction, Left | 2018 |
Vasopressin receptor antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Clinical Trials as Topic; Diabetes Insipidus, Nephrogenic; Fibrosis; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Pyrroles; Receptors, Vasopressin; Sodium; Tolvaptan; United States; United States Food and Drug Administration; Vasopressins | 2006 |
6 other study(ies) available for tolvaptan and Fibrosis
| Article | Year |
|---|---|
Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Doxorubicin; Fibrosis; Heart Failure; Inflammation; Kidney; Kidney Diseases; Mice; Stroke Volume; Tolvaptan; Valsartan; Ventricular Function, Left | 2022 |
Beneficial effects of tolvaptan on atrial remodeling induced by chronic intermittent hypoxia in rats.
Topics: Action Potentials; Animals; Atrial Fibrillation; Atrial Remodeling; Chronic Disease; Collagen; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Heart Atria; Heart Rate; Hypoxia; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase 9; MicroRNAs; Rats, Sprague-Dawley; Signal Transduction; Tolvaptan | 2018 |
Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Central Venous Pressure; Fibrosis; Heart Failure; Hemodynamics; Hypertension; Kidney Diseases; Kidney Medulla; Male; Protective Agents; Rats; Rats, Inbred Dahl; Sodium, Dietary; Stroke Volume; Tolvaptan; Ultrasonography; Vascular Resistance | 2019 |
In Vivo and In Vitro Effects of Vasopressin V2 Receptor Antagonism on Myocardial Fibrosis in Rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cardiomyopathies; Diet; Fibrosis; Heart Failure; Male; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Sodium Chloride; Tolvaptan | 2019 |
Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.
Topics: Acute-Phase Reaction; Animals; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Male; Myocardial Infarction; Rats; Rats, Wistar; Tolvaptan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2013 |
Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Hypertrophy, Left Ventricular; Kidney; Kidney Diseases; Male; Piperidines; Quinolones; Rats, Inbred Dahl; Receptors, Vasopressin; Time Factors; Tolvaptan; Ventricular Function, Left; Ventricular Remodeling | 2015 |